Pioglitazone is a prescription drug with hypo glycemic action from the thiazolidinedione class of compounds used in the treatment of diabetes mellitus (Type 2) and related diseases. Pioglitazone is administered orally at a dosage of 15 or 30 mg/day, with titration to 45 mg/day if necessary [1] . The compound is absorbed quickly from the gastrointestinal tract and shows bio availablity of greater than 80%, giving maxi mum plasma concentrations (C max ) within 2 h (t max ) of dosing [2] . A variety of methods have been established for the quantitative bioana lysis of pioglitazone in plasma and serum to determine ng/ml levels of the compound [3] [4] [5] [6] .
The dried blood spots (DBS) approach to toxicokinetic (TK) and pharmacokinetic (PK) sampling has recently received considerable attention owing to the inherent advantages of the technique. Preclinical DBS sampling has ethical advantages in the reduction and refine ment of animal use; less blood is sampled at each timepoint than for plasma or serum ana lysis meaning that serial, rather than compos ite, TK profiles can be obtained from individ ual animals [7] . Another advantage of the DBS approach is the potential to utilize finer needles to sample the blood, thereby causing less distress to the animals. The use of DBS in the clini cal arena has the advantage that it may elimi nate the requirement for sampling by venous cannula as it is feasible to sample peripheral blood (e.g., from a fingerprick) [8] . Less inva sive, simpler sampling would be of great benefit when conducting pediatric studies and would also allow home sampling by patients taking part in clinical trials. When compared with plasma or serum, the approach has a low biohazard risk, minimal postcollection processing with lower cost sample transport and storage [9] [10] [11] making PK sampling far easier in remote locations.
Bioanalytical methods for the ana lysis of compounds in DBS have been published for a number of drugs including acetaminophen, met formin, piperaquine, rifampicin, tacrolimus and dextromethorphan [7, [12] [13] [14] [15] [16] . Considerations when developing a DBS assay are the type of card to utilize (different card materials and chemical treatments), the spot diameter to be sampled from the card, the solvent to remove the analyte of interest from the paper, oncard stability of the analyte of interest during storage and how to dilute samples into the assay range, if required.
In this study, LC-MS/MS assays for the quantitative ana lysis of pioglitazone in DBS in the range 5 to 2500 ng/ml were established in two laboratories. Both assays were validated to conform to internationally recognized accep tance criteria [17] . A consideration when assess ing the accuracy and precision of bioanalytical results of unknown samples is whether the Application of the DBS methodology to a toxicokinetic study in rats and transferability of analysis between bioanalytical laboratories Background: There are little published data on either the comparison of liquid blood and dried blood spots (DBS) analyses or the ability to generate comparable DBS data at different analytical laboratories. We assess the comparative results of samples stored as liquid blood and DBS. We also determine the transferability of DBS samples by comparing the ana lysis at two laboratories. Results: Bioanalytical methods for the ana lysis of pioglitazone in DBS and liquid blood samples were validated to US FDA guidelines. Pharmacokinetic data generated from DBS and liquid blood samples demonstrated area under the time-concentration profile (0-24 h) values within 3% of each other and maximum plasma concentration values within 7% of each other. Comparing DBS sample results at different laboratories showed more than 99% of results agreeing within 20%. Conclusions: The results indicate that comparable concentration results are obtained from DBS and whole blood samples within the same laboratory, indicating that changing between the two matrices is viable. The comparable results of DBS samples analyzed at two laboratories using different analytical methodologies demonstrate that the technique is robust and transferable. 
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future science group ana lysis procedure is having an effect on the results. As there is no evidence in the literature that incurred DBS samples give comparable results when assayed by different methods, we assessed the transferability of DBS samples by analyzing the sample set at two laboratories. The two sets of results were compared to determine interlaboratory comparability of the DBS sam pling and ana lysis technique when using differ ent bioanalytical methods on the same study, as advised in the regulatory guidance [18] . The ability to directly compare results from liquid and dried blood samples was considered impor tant as larger sample volumes may be necessary when developing clinical assays to reach the required limits of quantification. Achieving a larger sample volume by changing the matrix to plasma is not considered suitable as the blood cell binding factor means that results from blood and plasma are not directly comparable. An additional comparison was made to deter mine whether dried and liquid blood samples gave comparable results by using two sampling techniques (DBS and blood:water 1:1 v/v) for harvesting PK blood samples following a single oral (gavage) administration of pioglitazone to the rat.
Experimental
Chemicals & reagents Pioglitazone (Figure 1) 
HPLC-MS/MS analysis

Laboratory 1
The HPLC-MS/MS system consisted of an Acquity UPLC system (PA, USA) coupled with a Sciex API4000 (Applied Biosystems/MDS Sciex, Canada). Chromatographic and MS conditions are detailed in taBleS 1 & 2, respec tively. HPLC-MS/MS data were acquired and processed using Analyst 1.4.2 software (Applied Biosystems). The chromatographic conditions utilized gradient chromatography with sepa ration achieved on an Acquity BEH C18 (50 × 2.1 mm, 1.7 µm) column with an aqueous mobile phase of 0.1% formic acid in 10 mM ammonium acetate and an organic mobile phase of 0.1% formic acid in methanol. The retention time of pioglitazone was 2.0 min.
Laboratory 2
The HPLC-MS/MS system consisted of an Acquity UPLC system coupled with a Sciex API5000. Chromatographic and MS condi tions are detailed in taBleS 1 & 2, respectively. HPLC-MS/MS data were acquired and pro cessed using Analyst 1. 4 Validated DBS & 1:1 blood:water (v/v) ana lysis procedures DBS methods were validated at both laboratories to US FDA guidelines [17] to include determina tion of precision and accuracy on three occasions, oncard stability assessment, determination of assay specificity and extract reinjection viability.
The analytical method for 1:1 blood:water (v/v) was validated at laboratory 1 to include determination of precision and accuracy on one occasion, freeze-thaw and room temperature stability assessment, determination of assay specificity and extract reinjection viability.
Laboratory 1
Stock solutions of pioglitazone were prepared in methanol (0.25 mg/ml) IS stock solutions of [ 2 H 4 ]pioglitazone (0.1 mg/ml) were prepared in methanol. All the solutions were stored at 4°C and brought to room temperature before use. Calibration standards were prepared fresh on the day of ana lysis by diluting the stock solu tions into appropriate concentration working solutions (with methanol), then spiking into blank whole rat blood to give a calibration line with standards at 5, 10, 20, 100, 250, 1000, 2000 and 2500 ng/ml, ensuring that the volume of the working solution remained less than 5% of the total standard volume. QC samples for all analyses were prepared from a second stock solution and were prepared by diluting the stock solution into appropriate concentration work ing solutions (with methanol), then spiking into blank whole rat blood to give QCs at 5 (valida tion only), 15, 125, 1800 and 12500 (valida tion only) ng/ml. For DBS analyses, 20 µl of calibration standards and QC samples were spotted onto FTA Elute cards and allowed to dry at room temperature for at least 2 h prior to ana lysis. 
Laboratory 2
Analytical column Acquity BEH C18, 50 x 2.1 mm, 1. The ability to switch from DBS ana lysis to ana lysis of whole blood at a later date of the drug development process was also inves tigated. The blood ana lysis involved tak ing 20 µl of 1:1 blood:water (v/v) and add ing 200 µl of methanol containing 50 ng/ ml IS ([ 2 H 4 ]pioglitazone). The samples were vortex mixed followed by centrifuga tion. A 20 of µl aliquot of the supernatant was transferred to a second 96well plate to which 180 of µl 0.1% formic acid in 80:20 10 mM ammonium formate:methanol (v/v) was added. The samples were vortex mixed followed by centrifugation and submitted for HPLC-MS/MS ana lysis.
Stock solutions of pioglitazone were prepared in dimethyl formamide (1 mg/ml). IS stock solutions of [ 2 H 4 ]pioglitazone (1 mg/ml) were prepared in dimethyl formamide. All the solu tions were stored at 4°C and brought to room temperature before use.
Calibration standards were prepared fresh on the day of ana lysis by diluting the stock solu tions into appropriate concentration working solutions (with 50:50 acetonitrile:ultrapure water v/v), then spiking into blank whole rat blood to give a calibration line with standards at 5, 10, 20, 100, 250, 1000, 2000 and 2500 ng/ ml, ensuring that the volume of the working solution remained less than 5% of the total standard volume. QC samples for all analyses were prepared from a second stock solution and 
In vivo test system
Female rats (six per group; HsdHan: WIST strain) were housed in a single, exclusive room, airconditioned to provide a minimum of 15 air changes/h. Female rats were specifically selected to assess any effects of the sampling procedures on smaller animals. The tempera ture and relative humidity ranges were main tained in the specified ranges of 19-25°C and 40-70%, respectively. Fluorescent lighting was controlled automatically to give a cycle of 12 h light (0600 h -1800 h) and 12 h dark and the animals were housed in groups of three.
Throughout the study the animals had access ad libitum to SQC Rat and Mouse Maintenance Diet No 1, Expanded, (Special Diets Services Ltd, Witham, UK) and mains water was provided ad libitum via water bot tles. Bedding was provided on a weekly basis to each cage by use of clean Aspen wood chips (Datesand Ltd, Manchester, UK) or European softwood bedding (BetaBed Grade 6, Datesand Ltd Manchester, UK). The diet, water and bedding was analyzed for specific contaminants and the results confirmed no contaminants were present at levels that might have interfered with achieving the objective of the study.
The animals were individually identified by electronic implant as follows:
Group 1F: animals one to six Group 2F: animals seven to 12 Ora l piog l it a z one for mu lat ion at 30 mg/kg was administered at a dose volume of 10 ml/kg and was selected to provide mea surable blood concentrations of pioglitazone, but was not expected to result in any toxicity. It was formulated as a suspension in 0.6 (w/w) gelatine and 0.9% sodium carboxymethylcel lulose in purified water and stored at 2-8°C in a sealed container. The formulation was stirred c ontinuously before and throughout dosing.
Blood sampling procedures
A single oral (gavage) dose at 30 mg/kg was administered to Group 1F. After dosing, DBS samples (three × 20 µl; three separate samples were taken at each timepoint with less than 30 s between the start of sample one and the end of sample three) were collected from the lateral caudal vein of each animal over a 24 h period. Each DBS sample was collected via a disposable 20µl glass capillary tube, onto a labelled FTA Elute sample card, allowed to air dry for a minimum of 2 h before being stored in sealed polypropylene bags/boxes contain ing desiccant sachets, these were kept at room temperature. In addition, whole blood samples (0.1 ml) were also collected from Group 1F over a 24 h period into tubes containing lith ium heparin. Samples (50 µl) of whole blood were added to purified water (50 µl), mixed gently by hand and placed on a cooled rack prior to storage at 20°C.
A single oral (gavage) dose at 30 mg/kg was administered to Group 2F. After dosing, DBS samples (three × 20 µl; three separate samples were taken at each timepoint with less than 30 s between the start of sample one and the end of sample three) were collected from the lateral caudal vein of each animal over a 24h period and processed as described above.
Blood was sampled at the following timepoints:
Group 1F: animals one to three at 0, 1, 2, 3.5, 5 and 7 h post dose (liquid blood and DBS); The data from Group 1F was used to generate composite PK profiles. The data from Group 2F was used to generate serial PK profiles.
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Results & discussion
DBS validations
All intra and interassay precision and accuracy data at both laboratories were within the pre defined 15% limits (20% at the LLOQ) and are presented in taBleS 3 & 4.
Effect of aliquot volume
Variation of the blood aliquot volume of up to ±25% of the 20µl target volume in laboratory 1 and ±33% of the target 15µl target volume in lab in lab oratory 2 did not affect the quantification of pio glitazone, indicating that the blood spot volume did not significantly affect the amount of analyte in the punched blood spot disk (taBleS 3 & 4) .
Response
The response of the detector to pioglitazone was linear for both laboratories methods over the concentration range 5 to 2500 ng/ml with a weighted 1/x 2 linear regression applied to the data (mean R 2 value 0.9968 and 0.9981 at laboratories 1 and 2, respectively). The analyte response (peak height) at the LLOQ was greater than fivetimes the blank blood spot response. Representative chromatograms are presented in Figure 2 (laboratory 1) and Figure 3 (laboratory 2) demonstrating an excellent signaltonoise ratio at the LLOQ and lack of significant interferences at the retention time of pioglitazone.
Selectivity
Neither method displayed significant interfer ent peaks (>20% of the mean utilized LLOQ) in matrix blanks in the retention window of pioglitazone and IS, respectively. There were no significant interferent peaks (>20% of the mean utilized LLOQ) detected in the six individual blank samples in the retention window of piogli tazone and IS, respectively. Matrix effects causing suppression and enhancement were determined to be less than 3.5% when comparing peak areas of postspiked QC extracts (n = 6) to pure standards (n = 6) of theoretical equivalent concentrations. Recovery was calculated at more than 75% when comparing peak areas of extracted QCs (n = 6) to postspiked QC extracts (n = 6) of theoretical equivalent concentrations. Table 3 . Intra-and inter-assay precision and accuracy quality control performance data for pioglitazone in rat dried blood spots and effect of blood aliquot volume on precision and accuracy of QC sample data at laboratory 1. Processed sample viability Viability of pioglitazone in the extracts produced via laboratory 1 was found to be acceptable when stored at nominal 4°C and reinjected 3 days after initial injection (precision and accuracy within the predefined 15% limits). The viability of pioglita zone in the extracts from laboratory 2 was accept able when stored at room temperature and rein jected 96 h after the initial injection (precision and accuracy within the predefined 15%).
Intra
Storage stability of pioglitazone in DBS Pioglitazone exhibits acceptable stability in DBS when stored at room temperature for up to 4 months (taBle 5).
Validation of 1:1 blood:water (v/v) (laboratory 1)
A partial validation of a method for the determi nation of pioglitazone in 1:1 blood:water (v/v) was performed to assess intraassay precision and accuracy (single batch), response, selec tivity, room temperature stability in matrix, freeze-thaw (three cycles) stability in matrix and processed extract viability. Intraassay precision and accuracy (single batch) data were within the predefined 15% limits (20% at the LLOQ).
Response
The response of the detector to pioglitazone was linear over the concentration range Table 4 . Intra-and inter-assay precision and accuracy quality control performance data for pioglitazone in rat dried blood spots and effect of blood aliquot volume on precision and accuracy of QC sample data at laboratory 2.
QC 5 ng/ml (LLOQ QC)
QC 20 ng/ml QC 250 ng/ml QC 2000 ng/ml QC 2500 ng/ml (HQC) QC 5000 ng/ml (DiQC) † Table 5 . Long-term stability of pioglitazone in dried blood spots stored at room temperature (data generated at laboratory 1). 
Intra-assay
Quality control level (ng
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future science group 5-2500 ng/ml. The analyte response (peak height) at the LLOQ was greater than fivetimes the blank 1:1 blood:water (v/v) response. Selectivity There were no significant interferent peaks (>20% of the mean utilized LLOQ or >5% of IS response) detected in reagent, matrix blanks and ULOQ calibration standard (without IS) in the retention window of pioglitazone and IS, respectively. There were no significant interfer ent peaks (>20% of the mean utilized LLOQ or >5% of IS response) detected in the six indi vidual blank samples in the retention window of pioglitazone and IS respectively. The accuracy values of each of the six spiked individual matrix samples were within 85-115% of the theoreti cal value. Therefore, individual matrix samples do not affect the quantification of pioglitazone.
Room temperature stability of pioglitazone in matrix
The data indicate that pioglitazone has accept able stability in 1:1 blood:water (v/v) stored at room temperature for up to 25 h (precision and accuracy within the predefined 15% limits).
Freeze-thaw stability of pioglitazone in matrix
The data indicate that pioglitazone has accept able stability in 1:1 blood:water (v/v) when exposed to up to three additional freeze/thaw cycles (precision and accuracy within the predefined 15% limits).
Processed sample viability
The viability of pioglitazone in the extracts was found to be acceptable when stored at nominal 4°C and reinjected 69 h after the initial injection (precision and accuracy within the predefined 15% limits).
PK results (laboratory 1) Blood concentrations of pioglitazone were quan tifiable in samples after dosing from all animals in Groups 1F and 2F, confirming systemic expo sure; the PK parameters are presented in taBle 4. Between-laboratory ana lysis of PK samples There was a good correlation (R 2 = 0.97) between DBS PK profile data generated at the two laboratories from the same samples (FigureS 5 & 6) . The correlation highlights the stability of pioglitazone in DBS samples as they were stored at room temperature for over 3 months between analyses at the two laborato ries. The acceptance criteria for demonstrating that an assay is adequate in terms of incurred sample reproducibility (ISR), where the same samples are analyzed on different occasions with the same assay, is that two thirds of results should be within 20% of each other. As differ ent occasions and laboratories with different methods and analysts for this work we are not demonstrating ISR, however, we demonstrate that the data generated at the two laboratories shows more than 99% of results are within 20% of each other, proving excellent correla tion on reana lysis of DBS samples. The correla tion is well within that deemed acceptable for ISR despite having far more variables.
Conclusion
A quantitative procedure for the determina tion of pioglitazone in DBS over the concen tration range 5 to 2500 ng/ml is demonstrated. Stability investigations carried out demonstrate that pioglitazone is stable in DBS for up to 4 months when stored at room temperature, enabling blood spot samples to be collected and stored prior to transportation. Blood spot vol Blood spot vol ume does not need to be accurate as long as the future science group same size core is taken from the spot, thereby allowing flexibility of blood spot preparation at the PK sampling stage allowing a capillary to be used rather than a calibrated pipette.
Collection of DBS samples from dosed ani mals enabled up to 12 samples to be taken from a single rat in a 24h period, with considerably less distress to the animal as smaller sample vol umes are required. The technique was shown to be a viable alternative to the current procedures used for PK/TK sampling from rats. Using DBS, an entire PK/TK profile can be obtained from a single rat, rather than composite profiles, which should improve the quality of the data obtained and also reduce the number of rats used in a study.
The data presented indicate a good correlation between DBS PK profile data analyzed at two laboratories, successfully demonstrating the ana lytical interlaboratory reliability of the DBS sam pling and ana lysis technique when using different bioanalytical methods on the same study.
Future perspective
Pharmacokinetic data generated gives a good correlation between blood concentration data from the two sample types DBS and liquid blood, demonstrating that DBS ana lysis is a suitable alternative to the more traditional liq uid sample type and that DBS samples provide comparable exposure data to conventional blood samples. Therefore, if required at a later stage in the drug development process (e.g., moving from preclinical to clinical sample ana lysis and the associated lower concentration levels) switching DBS sampling to whole blood sampling is pos sible. The good correlation between the DBS PK data generated at the two laboratories indicates that ISR should not cause issues when using the DBS approach. future science group
Ethical conduct of research
Executive summary
Methods were determined at two laboratories to determine pioglitazone in dried blood spots (DBS) over the range of 5-2500 ng/ml.
A method was also determined at one laboratory to determine pioglitazone in 1:1 blood:water (v/v) over the range of 5-2500 ng/ml.
All methods displayed results within regulatory acceptance criteria.
Serial profiles were able to be constructed for individual rats using the DBS method.
Accurate blood sampling was shown to be unnecessary.
Storage stability of pioglitazone in DBS was shown for at least 4 months.
The transferability of DBS ana lysis between laboratories using different analytical instrumentation, personnel and methodology showed excellent correlation with more than 99% of results within 20% of each other.
Pharmacokinetic data generated by liquid blood and DBS sampling analyses gave excellent correlation. 
